The distribution of lipoprotein (a)[Lp (a)] levels can differ dramatically across diverse
racial/ethnic populations. The extent to which genetic variation in LPA can explain these …

Lipoprotein (a)(Lp (a)) is an important causal cardiovascular risk factor, with serum Lp (a)
levels predicting atherosclerotic heart disease and genetic determinants of Lp (a) levels …

Background Atherosclerotic plaque vulnerability is a key feature of atheroprogression and
precipitating acute cardiovascular events. Although the pivotal role of epigenetic regulation …

Abstract Purpose of Review Epigenetic modifications via DNA methylation have previously
been linked to blood lipid levels, dyslipidemias, and atherosclerosis. The purpose of this …

The extent to which genetic influences on complex traits and disease are mediated by
changes in DNA methylation levels has not been systematically explored. We developed an …

Objective—The objectives of this study were to decipher whether age-independent
cardiovascular risk is associated with DNA methylation at 5′-cytosine-phosphate-guanine …

The present work investigates the occurrence and significance of aberrant DNA methylation
patterns during early stages of atherosclerosis. To this end, we asked whether the …

Lipoprotein subfractions help discriminate cardiometabolic disease risk. Genetic loci
validated as associating with lipoprotein measures do not account for a large proportion of …

DNA methylation commonly occurs at cytosine-phosphate-guanine sites (CpGs) that can
serve as biomarkers for many diseases. We analyzed whole genome sequencing data to …

Background: Genomic analyses have suggested that the LPA gene and its associated
plasma biomarker, lipoprotein (a)(Lp [a]), represent a causal risk factor for coronary heart …